The main purpose of this investigation is to collect safety and efficacy information of Eslax Intravenous 25mg/2.5mL and 50mg/5.0mL (hereinafter referred to as "Eslax") in daily clinical settings.
Post-marketing surveys are not considered applicable clinical trials and thus the results of this survey will not be posted at its conclusion. The results will be submitted to public health officials as required by applicable national and international laws.
Study Type
OBSERVATIONAL
Enrollment
3,969
Normally, for adults, 0.6 mg/kg of rocuronium bromide is intravenously administered to support endotracheal intubation. If additional administration is necessary, 0.1 - 0.2 mg/kg is intravenously administered. In the case of continuous infusion, infusion is initiated at a rate of 7 μg/kg/min. Dosage should be adjusted based on the age or symptom. The upper limit of this drug for the intubation is 0.9 mg/kg.
incidence of adverse events
Time frame: The standard observation period for a patient is duration of hospital stay (from one week before Eslax administration to one week after administration at a maximum).
intubation score
Time frame: From administration of Eslax to completion of intubation
intubation completion time
Time frame: From administration of Eslax to completion of intubation
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.